Shareholder rights law firm Robbins Arroyo LLP is investigating potential violations of federal securities laws on behalf of investors of Biota Pharmaceutical, Inc. (NASDAQ:BOTA). Biota Pharmaceuticals Inc (NASDAQ:BOTA) net profit margin is -19.60% and weekly performance is -13.25%. On last trading day company shares ended up $2.88. Analysts mean target price for the company is $7.00. Biota Pharmaceuticals Inc (NASDAQ:BOTA) distance from 50-day simple moving average (SMA50) is -48.19%.
USMD Holdings Inc. (NASDAQ:USMD), a physician-led integrated health system headquartered in Irving, has acquired the assets of Associates in Urology, a Fort Worth-based urology practice group, for an undisclosed amount. As a result of the acquisition, Dr. John Pumphrey and Dr. Michael Walter will join USMD’s physician group, bringing the total number of USMD urologists to 57. Pumphrey is board certified in urology and has more than 20 years of experience treating patients. He completed his medical training at Texas Tech School of Medicine and his residency in urology at University of Louisville. USMD Holdings Inc (NASDAQ:USMD) shares advanced 1.25% in last trading session and ended the day on $12.18. USMD return on assets is 0.30%. USMD Holdings Inc (NASDAQ:USMD) quarterly performance is -31.23%.
Equities research analysts at MLV & Co reduced their price target on shares of ArQule Inc (NASDAQ:ARQL) from $3.00 to $1.75 in a research note issued to investors on Monday, AnalystRatings.Net reports. The firm currently has a “hold” rating on the stock. MLV & Co ‘s price target points to a potential upside of 25.00% from the company’s current price. ArQule, Inc. (NASDAQ:ARQL) shares moved up 7.14% in last trading session and was closed at $1.50, while trading in range of $1.38 – $1.51. ArQule, Inc. (NASDAQ:ARQL) year to date (YTD) performance is -30.23%.
On May 7, China Gerui Advanced Materials Group Limited (NASDAQ:CHOP) a leading high- precision, cold-rolled steel producer in China, announced preliminary unaudited first quarter 2014 revenues of approximately $26 million and reiterated 2014 revenue guidance of $175 – $180 million. China Gerui Adv Mtals Grp Ltd (NASDAQ:CHOP) ended the last trading day at $0.710. Company weekly volatility is calculated as 6.69% and price to cash ratio as 0.19. China Gerui Adv Mtals Grp Ltd (NASDAQ:CHOP) showed a negative weekly performance of -7.79%.
Leave a Reply